Insight

Mohammad Jad Moussa: Combining ICIs with Antiangiogenic Agents in Advanced Urothelial Cancer

Mohammad Jad Moussa/X

Dec 22, 2024, 11:44

Mohammad Jad Moussa: Combining ICIs with Antiangiogenic Agents in Advanced Urothelial Cancer

Mohammad Jad Moussa, Oncology Fellow at MD Anderson Cancer Center, shared a post on X:

“Now in Bladder Cancer Journal of Bladder Cancer Advocacy Network.

Can Combining ICIs with Antiangiogenic Agents Revive Antiangiogenic Therapy in Advanced Urothelial Cancer?

1st Meta-Analysis: ORR 34% in ICI-naïve group vs 16% in ICI-exposed.

Better patient selection.”

Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic review and meta-analysis

Authors: Mohammad Jad Moussa, Iuliia Kovalenko, Emanuele Crupi, Ekaterina Proskuriakova, Yimin Geng, Giuseppe Fallara, Raed Benkhadra, Daniele Raggi, Matthew T. Campbell, Pavlos Msaouel, Omar Alhalabi

Mohammad Jad Moussa

Bladder Cancer Advocacy Network Bladder Cancer Journal cancer Daniele Raggi Ekaterina Proskuriakova Emanuele Crupi Giuseppe Fallara Iuliia Kovalenko Matthew T Campbell Mohammad Jad Moussa Omar Alhalabi OncoDaily Oncology patient selection Pavlos Msaouel Raed Benkhadra Yimin Geng

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

Karen Knudsen: Clinical trials are the most advanced form of cancer care

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results